{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:09:59Z","timestamp":1792800599259,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["K08CA252161"],"award-info":[{"award-number":["K08CA252161"]}]},{"name":"NCI Cancer Center Core Support Grant","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}]},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Friends of Urology Foundation","id":[{"id":"https:\/\/ror.org\/01jat6m31","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Approximately 90% of bladder cancer deaths are due to distant metastases rather than local tumor effects. The current first-line systemic treatment for metastatic bladder cancer (mBC) is chemoimmunotherapy or immunotherapy with pembrolizumab plus enfortumab vedotin (EV). However, most mBC patients treated with chemoimmunotherapy or pembrolizumab\/EV do not respond or eventually relapse, highlighting the critical need for robust immunocompetent animal models to elucidate the mechanisms of primary and acquired resistance. We previously generated a syngeneic murine cell line CMV-TRP (triple knockout of\n                    <jats:italic>Trp53<\/jats:italic>\n                    ,\n                    <jats:italic>Rb1<\/jats:italic>\n                    ,\n                    <jats:italic>Pten<\/jats:italic>\n                    ) via ex vivo transduction with adenovirus (Ad5CMVCre). To establish an mBC model, the TKO cells were effectively labeled with a lentiviral luciferase and GFP double-expressing reporter and injected into tail veins of C57 BL\/6J mice. Tail vein injection of TKO cells reliably established distant metastases with lung and bone lesions. In immunotherapy experiments, mice injected with TKO-labeled cell lines were randomly treated with an anti\u2013PD-1 or control IgG2a antibody. All mice developed lung and\/or bone (hind limb or sacrum) metastases. There was no difference in tumor bioluminescence between the control group and anti\u2013PD-1 group (median proton\/second 6.94\u2009\u00d7\u200910\n                    <jats:sup>8<\/jats:sup>\n                    vs. 4.32\u2009\u00d7\u200910\n                    <jats:sup>8<\/jats:sup>\n                    ,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.85). Kaplan-Meier analysis showed no difference in median survival between the control group and anti\u2013PD-1 group (19 days vs. 20 days,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.47). Histology and immunohistochemical profile of lung and bone metastases revealed high-grade basal-like urothelial carcinoma, closely resembling the profile observed in subcutaneous tumor. No significant changes in immune cell infiltrations (CD4\n                    <jats:sup>+<\/jats:sup>\n                    , CD8\n                    <jats:sup>+<\/jats:sup>\n                    , or F4\/80\n                    <jats:sup>+<\/jats:sup>\n                    ) between groups may explain anti\u2013PD-1 immunotherapy resistance. Therefore, the novel TKO metastatic model represents a useful and reproducible tool for studying tumor-cell dissemination, bone\/lung metastasis, and the underlying mechanisms of anti\u2013PD-1 immunotherapy resistance.\n                  <\/jats:p>","DOI":"10.1186\/s12935-025-04117-x","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:16:04Z","timestamp":1767860164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model"],"prefix":"10.1186","volume":"26","author":[{"given":"Dongbo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine J.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshid","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"1","key":"4117_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"4117_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4117_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.eururo.2011.05.005","volume":"60","author":"G van der Horst","year":"2011","unstructured":"van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, Bevers RF, Pelger RC, van der Pluijm G. Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol. 2011;60(2):337\u201343.","journal-title":"Eur Urol"},{"key":"4117_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193333","author":"Y Yamauchi","year":"2024","unstructured":"Yamauchi Y, Sato M, Iwata T, Endo M, Ikeda N, Hashimoto H, et al. Survival after lung metastasectomy from urothelial carcinoma: a multi-institutional database study. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16193333.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4117_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.mpmed.2011.09.008","volume":"40","author":"R Turo","year":"2012","unstructured":"Turo R, Cross W, Whelan P. Bladder cancer. Medicine. 2012;40(1):14\u20139.","journal-title":"Medicine"},{"key":"4117_CR6","doi-asserted-by":"publisher","first-page":"175883592110473","DOI":"10.1177\/17588359211047352","volume":"13","author":"C Stecca","year":"2021","unstructured":"Stecca C, Abdeljalil O, Sridhar SS. Metastatic urothelial cancer: a rapidly changing treatment landscape. Ther Adv Med Oncol. 2021;13:17588359211047352.","journal-title":"Ther Adv Med Oncol"},{"issue":"17","key":"4117_CR7","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068\u201377.","journal-title":"J Clin Oncol"},{"key":"4117_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/CMAR.S148856","volume":"9","author":"F Dong","year":"2017","unstructured":"Dong F, Shen Y, Gao F, Xu T, Wang X, Zhang X, Zhong S, Zhang M, Chen S, Shen Z. Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study. Cancer Manag Res. 2017;9:611\u201326.","journal-title":"Cancer Manag Res"},{"issue":"3\u20134","key":"4117_CR9","doi-asserted-by":"publisher","first-page":"E148","DOI":"10.5489\/cuaj.787","volume":"8","author":"M Bianchi","year":"2014","unstructured":"Bianchi M, Roghmann F, Becker A, Sukumar S, Briganti A, Menon M, et al. Age-stratified distribution of metastatic sites in bladder cancer: a population-based analysis. Can Urol Assoc J. 2014;8(3\u20134):E148-158.","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"4117_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875\u201388.","journal-title":"N Engl J Med"},{"issue":"19","key":"4117_CR11","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778\u201389.","journal-title":"N Engl J Med"},{"key":"4117_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010054","author":"L Yi","year":"2022","unstructured":"Yi L, Ai K, Li X, Li Z, Li Y. Bone metastasis in bladder cancer. J Pers Med. 2023;13(1):54. https:\/\/doi.org\/10.3390\/jpm13010054","journal-title":"J Pers Med"},{"issue":"1","key":"4117_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s12672-024-00902-8","volume":"15","author":"L Tang","year":"2024","unstructured":"Tang L, Xu H, Wu T, Wu W, Lu Y, Gu J, Wang X, Zhou M, Chen Q, Sun X, et al. Advances in tumor microenvironment and underlying molecular mechanisms of bladder cancer: a systematic review. Discov Oncol. 2024;15(1):111.","journal-title":"Discov Oncol"},{"issue":"3\u20134","key":"4117_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10555-007-9084-9","volume":"26","author":"PC Black","year":"2007","unstructured":"Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis\u2013translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26(3\u20134):623\u201334.","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"4117_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/j.1464-410X.2009.08577.x","volume":"104","author":"E Chan","year":"2009","unstructured":"Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models for bladder cancer research. BJU Int. 2009;104(9):1286\u201391.","journal-title":"BJU Int"},{"issue":"6","key":"4117_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000164218","volume":"75","author":"M Chikazawa","year":"2008","unstructured":"Chikazawa M, Inoue K, Fukata S, Karashima T, Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology. 2008;75(6):335\u201345.","journal-title":"Pathobiology"},{"issue":"1","key":"4117_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12967-019-02177-y","volume":"17","author":"JL Tatum","year":"2019","unstructured":"Tatum JL, Kalen JD, Jacobs PM, Ileva LV, Riffle LA, Hollingshead MG, Doroshow JH. A spontaneously metastatic model of bladder cancer: imaging characterization. J Transl Med. 2019;17(1):425.","journal-title":"J Transl Med"},{"key":"4117_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0076-6879(07)00417-X","volume":"439","author":"MD Nitz","year":"2008","unstructured":"Nitz MD, Harding MA, Theodorescu D. Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods Enzymol. 2008;439:219\u201333.","journal-title":"Methods Enzymol"},{"issue":"10","key":"4117_CR19","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/sj.bjc.6603423","volume":"95","author":"K Sato","year":"2006","unstructured":"Sato K, Yuasa T, Nogawa M, Kimura S, Segawa H, Yokota A, Maekawa T. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006;95(10):1354\u201361.","journal-title":"Br J Cancer"},{"issue":"1","key":"4117_CR20","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1038\/s41467-018-05366-3","volume":"9","author":"T Kuchimaru","year":"2018","unstructured":"Kuchimaru T, Kataoka N, Nakagawa K, Isozaki T, Miyabara H, Minegishi M, Kadonosono T, Kizaka-Kondoh S. A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries. Nat Commun. 2018;9(1):2981.","journal-title":"Nat Commun"},{"issue":"3","key":"4117_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of Muscle-Invasive bladder cancer. Cell. 2017;171(3):540\u2013e556525.","journal-title":"Cell"},{"key":"4117_CR22","doi-asserted-by":"crossref","unstructured":"Xu D, Wang L, Wieczorek K, Wang Y, Zhang X, Goodrich DW, Li Q. Ex vivo organoid model of Adenovirus-Cre mediated gene deletions in mouse urothelial cells. J Vis Exp. 2022;(183):e63855.","DOI":"10.3791\/63855-v"},{"issue":"10","key":"4117_CR23","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cancers14102511","volume":"14","author":"D Xu","year":"2022","unstructured":"Xu D, Wang L, Wieczorek K, Zhang Y, Wang Z, Wang J, et al. Single-cell analyses of a novel mouse urothelial carcinoma model reveal a role of tumor-associated macrophages in response to anti-PD-1 therapy. Cancers. 2022;14(10):2511.","journal-title":"Cancers"},{"issue":"3","key":"4117_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1755-148X.2009.00545.x","volume":"22","author":"CP Day","year":"2009","unstructured":"Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G. Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res. 2009;22(3):283\u201395.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"4117_CR25","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1158\/1535-7163.MCT-21-0613","volume":"21","author":"D Xu","year":"2022","unstructured":"Xu D, Cao Q, Wang L, Wang J, Xu B, Attwood K, Wei L, Wu Y, Smith GJ, Katsuta E, et al. A preclinical study to repurpose spironolactone for enhancing chemotherapy response in bladder cancer. Mol Cancer Ther. 2022;21(5):786\u201398.","journal-title":"Mol Cancer Ther"},{"issue":"695","key":"4117_CR26","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, Chen F, Zhang J, Mak DH, Van V, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15(695):eadf6724.","journal-title":"Sci Transl Med"},{"key":"4117_CR27","doi-asserted-by":"crossref","unstructured":"John BA, Said N. Insights from animal models of bladder cancer: recent advances, challenges, and opportunities. Oncotarget. 2017;8(34):57766\u201381.","DOI":"10.18632\/oncotarget.17714"},{"issue":"1","key":"4117_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12894-022-01093-6","volume":"22","author":"J Cai","year":"2022","unstructured":"Cai J, Xie Z, Yan Y, Huang Z, Tang P, Cao X, Wang Z, Yang C, Tan M, Zhang F, et al. Establishment of an optimized orthotopic bladder cancer model in mice. BMC Urol. 2022;22(1):142.","journal-title":"BMC Urol"},{"issue":"21","key":"4117_CR29","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1158\/0008-5472.CAN-04-0826","volume":"64","author":"BE Nicholson","year":"2004","unstructured":"Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Res. 2004;64(21):7813\u201321.","journal-title":"Cancer Res"},{"issue":"11","key":"4117_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1158\/2159-8290.CD-18-0044","volume":"8","author":"B Olson","year":"2018","unstructured":"Olson B, Li Y, Lin Y, Liu ET, Patnaik A. Mouse models for cancer immunotherapy research. Cancer Discov. 2018;8(11):1358\u201365.","journal-title":"Cancer Discov"},{"issue":"14","key":"4117_CR31","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","volume":"78","author":"R Saito","year":"2018","unstructured":"Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, et al. Molecular Subtype-Specific immunocompetent models of High-Grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2018;78(14):3954\u201368.","journal-title":"Cancer Res"},{"issue":"5","key":"4117_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/2326-6066.CIR-15-0176","volume":"4","author":"AJ Vandeveer","year":"2016","unstructured":"Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW. Systemic immunotherapy of non-muscle invasive mouse bladder cancer with Avelumab, an anti-PD-L1 immune checkpoint inhibitor. Cancer Immunol Res. 2016;4(5):452\u201362.","journal-title":"Cancer Immunol Res"},{"key":"4117_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122245","author":"E Desponds","year":"2024","unstructured":"Desponds E, Kioseoglou K, Zdimerova H, Ongaro M, Verdeil G, Leblond MM. Development of traceable mouse models of advanced and metastatic bladder cancer. Cancers (Basel). 2024;16(12):2245. https:\/\/doi.org\/10.3390\/cancers16122245","journal-title":"Cancers (Basel)"},{"issue":"11","key":"4117_CR34","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"10122","key":"4117_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357.","journal-title":"Lancet"},{"issue":"4","key":"4117_CR36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","volume":"174","author":"AG Robertson","year":"2018","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2018;174(4):1033.","journal-title":"Cell"},{"issue":"10","key":"4117_CR37","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","volume":"8","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials. JAMA Oncol. 2022;8(10):1456\u201365.","journal-title":"JAMA Oncol"},{"key":"4117_CR38","doi-asserted-by":"crossref","unstructured":"Ansari AM, Ahmed AK, Matsangos AE, Lay F, Born LJ, Marti G, Harmon JW, Sun Z. Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev Rep. 2016;12(5):553\u20139.","DOI":"10.1007\/s12015-016-9670-8"},{"key":"4117_CR39","doi-asserted-by":"crossref","unstructured":"Limberis MP, Bell CL, Wilson JM. Identification of the murine firefly luciferase-specific CD8 T-cell epitopes. Gene Ther. 2009;16(3):441\u20137.","DOI":"10.1038\/gt.2008.177"},{"key":"4117_CR40","doi-asserted-by":"crossref","unstructured":"Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer. 2010;9:299.","DOI":"10.1186\/1476-4598-9-299"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-04117-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04117-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-04117-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:32:58Z","timestamp":1770341578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-025-04117-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4117"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-04117-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at RPCCC (#1395).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}